Past Air, Inc. XAIR will launch its fourth-quarter monetary outcomes after the closing bell on Tuesday, June 17.
Analysts count on the Backyard Metropolis, New York-based firm to report quarterly income of $1.39 million, in comparison with $470,000 a yr earlier, based on knowledge from Benzinga Professional.
On April 21, Past Air introduced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.
Past Air shares fell 3% to shut at $0.1779 on Friday.
Benzinga readers can entry the most recent analyst rankings on the Analyst Inventory Rankings web page. Readers can kind by inventory ticker, firm identify, analyst agency, score change or different variables.
Let’s take a look at how Benzinga’s most-accurate analysts have rated the corporate within the latest interval.
Immediately’s Greatest Finance Offers
- BTIG analyst Marie Thibault downgraded the inventory from Purchase to Impartial on June 25, 2024. This analyst has an accuracy price of 63%.
- Truist Securities analyst Gregory Fraser maintained a Purchase score and lowered the worth goal from $10 to $8 on April 30, 2024. This analyst has an accuracy price of 63%.
Contemplating shopping for XAIR inventory? Right here’s what analysts assume:
Learn This Subsequent:
Picture through Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
